[Biochemical, pharmacologic and clinical properties of new thrombolytic agents].
Gulba
D C
DC
Virchow-Klinikum der Humboldt-Universität zu Berlin.
D000595:Amino Acid Sequence / Q000235:genetics; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics; D010960:Plasminogen Activators / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C087896:reteplase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; C067551:saruplase
Biochemische, pharmakologische und klinische Eigenschaften neuer Thrombolytika.